SCHEMBL13509018

SCHEMBL13509018

CC(C)n1nc(-c2ccccc2)c(-c2nccs2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.53
▸ CYP2A6 P11509 1/20 0.41
▸ ADORA1 P30542 6/20 0.40
▸ ADORA2A P29274 3/20 0.40
▸ ADORA3 P0DMS8 3/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ KDR P35968 1/20 0.39
▸ MAT2A P31153 1/20 0.36
▸ ADRB2 P07550 2/20 0.36
▸ HPGD P15428 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ECE1 P42892 1/20 0.35
▸ MERTK Q12866 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13510669 0.84 PDPK1 (0.54) PDPK1CYP2A6ADORA1ADORA2AADORA3
SCHEMBL14271033 0.83 ADRB2 (0.43) PDPK1ADORA1ADORA2AADORA3ADORA2B
SCHEMBL10045002 0.83 GABRA1 (0.42) ADORA1ADORA2AADORA3ADORA2BKDR
SCHEMBL8214626 0.83 PDPK1 (0.58) PDPK1CYP2A6ADORA1ADORA2AADORA3
SCHEMBL13222027 0.80 RECQL (0.43) ADORA3MEN1ALDH1A1LMNAMAPT
SCHEMBL13509080 0.76 ALDH1A1 (0.43) ADORA1ADORA2AADORA2BHPGDMEN1
SCHEMBL13509082 0.74 CYP2A6 (0.48) CYP2A6ADORA1ADORA2AMAPT
SCHEMBL13509079 0.73 MAPK14 (0.41) ADORA2AADORA2B
SCHEMBL14270968 0.71 ALDH1A1 (0.48) ADORA1ADORA2AMEN1ALDH1A1MAPT
2-Phenylthiazole SCHEMBL70646 0.71 PDPK1 (1.00) PDPK1CYP2A6KDRADRB2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662779-B2 Triazolyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2010-02-16 — — US disclosed
US-20090047248-A1 TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047248-A1 TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS SPINT2, PRSS1, CTSC PDPK1 2527/4885CYP2A6 308/4885ADORA1 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback